Nuvation Bio Inc. (NUVB) Stock Forecast
NUVB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.62 / 5 from 13 analysts
- Price target
- $13.00 average of analyst targets
- Upside to target
- +192.1% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-0.12
- 52-week range
- $3.70 – $9.54
NUVB analyst ratings
13 analystsNumber of analysts at each rating.
NUVB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NUVB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.09 | −$0.09 | −$0.14 | +35.5% | 2 |
| Current fiscal year (2026) | −$0.29 | −$0.29 | −$0.29 | −$0.49 | +41.3% | 2 |
| Next fiscal year (2027) | −$0.01 | −$0.08 | $0.05 | −$0.29 | +94.8% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NUVB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $34.8M | $27.9M | $39.8M | +165.3% | 13 |
| Current fiscal year (2026) | $195.5M | $176.2M | $220.8M | +210.9% | 13 |
| Next fiscal year (2027) | $282.4M | $221.9M | $354.6M | +44.4% | 13 |
NUVB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NUVB revenue: reported and forecast
NUVB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.11 | −$0.11 | −$0.11 | −$0.09 | −18.2% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.28 | −$0.28 | −$0.28 | −$0.28 | −$0.29 | +3.6% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.06 | −$0.06 | −$0.06 | −$0.06 | −$0.01 | −75.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NUVB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NUVB beat in 8 of 12.
What analysts expect from NUVB
13 analysts cover Nuvation Bio; their consensus rating is strong buy (4.62 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.00, 192.1% above the latest close of $4.45. Analysts expect earnings of −$0.29 per share for 2026, +41.3% from a year earlier. For 2027 the average estimate is −$0.01 per share on revenue of $282.4 million. Nuvation Bio beat the EPS estimate in 8 of the last 12 quarters.
Related: NUVB income statement, NUVB key metrics, NUVB chart. See the NUVB stock overview for the latest quote and news.
NUVB forecast FAQ
What is Nuvation Bio's price target?
The average analyst price target for Nuvation Bio is $13.00, 192.1% above the latest close of $4.45.
Is Nuvation Bio a buy, hold or sell?
Of 13 analysts covering Nuvation Bio, 9 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Nuvation Bio's EPS forecast?
Analysts forecast −$0.29 per share for 2026 (range −$0.29 to −$0.29); for 2027 the estimate is −$0.01.
What is Nuvation Bio's revenue forecast?
The average revenue estimate for 2026 is $195.5 million, growth of 210.9%; for 2027 it is $282.4 million.
When does Nuvation Bio report earnings?
Nuvation Bio is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens; the EPS estimate is $-0.12.
Does Nuvation Bio usually beat earnings estimates?
Nuvation Bio reported EPS at or above the analyst estimate in 8 of the last 12 quarters.